Considering lab-based findings of the behavioral effects of dopamine agonists, we predicted that dopamine agonist treatment would improve motivational symptoms but not other depression symptom dimensions, whereas MAO-B inhibitors may improve mood due to their concurrent serotonergic action at higher doses29. The gene discussed is MAOB; the disease is major depressive disorder.